In Brief:
Treatment with laser photocoagulation and/or intravitreal bevacizumab was effective at treating Type 1 idiopathic macular telangiectasia. The mean visual acuity was maintained from baseline. The mean central retinal thickness of eyes treated with intravitreal bevacizumab monotherapy, and intravitreal bevacizumab followed by laser photocoagulation, was significantly reduced. However, 36.7% of idiopathic macular telangiectasia eyes did not require treatment over a 2-year follow-up.
Go to Full Text of this Article